790 related articles for article (PubMed ID: 31298061)
1. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
Doymaz MZ; Karaaslan E
Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
[No Abstract] [Full Text] [Related]
2. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of disc diffusion, E-test, and broth microdilution methods for the determination of resistance to colistin, polymyxin B, and tigecycline in multi-resistant Acinetobacter baumannii isolates].
Akin FE; Bayram A; Balci I
Mikrobiyol Bul; 2010 Apr; 44(2):203-10. PubMed ID: 20549954
[TBL] [Abstract][Full Text] [Related]
4. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
6. Performances of the Rapid Polymyxin
Lescat M; Poirel L; Jayol A; Nordmann P
Microb Drug Resist; 2019 May; 25(4):520-523. PubMed ID: 30508392
[No Abstract] [Full Text] [Related]
7. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.
Vidaillac C; Benichou L; Duval RE
Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540
[TBL] [Abstract][Full Text] [Related]
8. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
9. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
Zhang Y; Zhao C; Wang Q; Wang X; Chen H; Li H; Zhang F; Wang H
J Antimicrob Chemother; 2020 Sep; 75(9):2609-2615. PubMed ID: 32591806
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care centre in Western Turkey.
Ece G; Samlioglu P; Atalay S; Kose S
Infez Med; 2014 Mar; 22(1):36-40. PubMed ID: 24651089
[TBL] [Abstract][Full Text] [Related]
12. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.
Sader HS; Rhomberg PR; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2015 Dec; 83(4):379-81. PubMed ID: 26415906
[TBL] [Abstract][Full Text] [Related]
13. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
[TBL] [Abstract][Full Text] [Related]
15. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
Gales AC; Reis AO; Jones RN
J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
[TBL] [Abstract][Full Text] [Related]
17.
Duncan LR; Wang W; Sader HS
Antimicrob Agents Chemother; 2022 May; 66(5):e0013922. PubMed ID: 35475635
[TBL] [Abstract][Full Text] [Related]
18. Synergistic combinations of polymyxins.
Lenhard JR; Nation RL; Tsuji BT
Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Etest method for detecting colistin susceptibility of multidrug-resistant Gram-negative isolates in Vietnam.
Nhung PH; Miyoshi-Akiyama T; Phuong DM; Shimada K; Anh NQ; Binh NG; Thanh do V; Ohmagari N; Kirikae T
J Infect Chemother; 2015 Aug; 21(8):617-9. PubMed ID: 25960156
[TBL] [Abstract][Full Text] [Related]
20. Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and
Chew KL; La MV; Lin RTP; Teo JWP
J Clin Microbiol; 2017 Sep; 55(9):2609-2616. PubMed ID: 28592552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
